Recent Updates
Recently added Catalysts
IPHA Neutral Sentiment Score: 60/100

Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results MARSEILLE, France--(BUSINESS WIRE)

Thursday, March 16, 2023 4 min read
Key Takeaway: Innate Pharma has announced a conference call scheduled for March 23, 2023, to discuss its financial results for the year ending December 31, 2022. The call will feature key company executives, including the CEO and CFO, highlighting the company's commitment to transparency and investor relations. Innate Pharma is recognized for its innovative cancer therapies and has a robust pipeline involving various industry collaborations. However, the company also warns of inherent risks and uncertainties associated with its development projects and financial status.

Market Sentiment Analysis

POSITIVE FACTORS

  • Innate Pharma is conducting a conference call which indicates transparency and engagement with stakeholders.
  • The company has a broad pipeline of potentially first-in-class clinical and preclinical candidates.
  • Along with quality leadership, the inclusion of high-profile partnerships suggests strong industry connections.

CONCERNS & RISKS

  • The announcement comes with caution regarding forward-looking statements and associated risks.
  • Uncertainties related to research and development, as well as regulatory approvals, could impact results.
  • The company's future capabilities to raise capital are uncertain and subject to market conditions.

Full Press Release Details

Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results

MARSEILLE, France--(BUSINESS WIRE)--March 16, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Thursday, March 23, 2023 at 2
p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2022.
Speakers during the call will be:
Mondher Mahjoubi, Chief Executive Officer
Joyson Karakunnel, Executive Vice President, Chief Medical Officer
Yannis Morel, Executive Vice President, Product Portfolio Strategy & Business Development
Fr d ric Lombard, Senior Vice President, Chief Financial Officer
Details for the Virtual Event
The live webcast will be available at the following link:
https://events.q4inc.com/attendee/611394672
Participants may also join via telephone using the following registration link: https://registrations.events/direct/Q4E60253
This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event.
About Innate Pharma:
Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.
Innate Pharma's broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
Innate is a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.
Headquartered in Marseille, France, with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com.
Information about Innate Pharma shares:
Disclaimer on forward-looking information and risk factors:
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "believe," "potential," "expect" and "will" and
similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which
could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results
from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund
its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please
refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website http://www.amf-france.org or on Innate Pharma's
website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings and reports filed with the
AMF or SEC, or otherwise made public, by the Company.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Contacts

Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Tel.: +33 (0)1 44 71 00 15

Frequently Asked Questions

When will Innate Pharma's conference call take place?

The conference call will occur on March 23, 2023, at 2 p.m. CET.

Who will speak during the conference call?

Speakers include CEO Mondher Mahjoubi and other executives.

Where can I watch the webcast of the event?

The live webcast is available at Innate Pharma's event link.

How long will the webcast replay be available?

The webcast replay can be accessed for 90 days post-event.

What does Innate Pharma focus on?

Innate Pharma specializes in oncology therapies using therapeutic antibodies.

Tags: IPHA Viatris Investor Conferences Healthcare Innate Pharma clinical-stage biotech financial results oncology
Last updated: Mar 16, 2023